上海交通大学医学院分子医学研究院新建于2017年10月，由中国科学院院士谭蔚泓教授领衔建立，并依托上海交通大学医学院附属仁济医院实体建设。研究院聚焦分子医学前沿，立足于重大疾病创新药物研发与早诊确诊防控技术的突破，从基础前沿研究到知识产权和产业化落地，全程助推健康中国建设。研究院建有上海市核酸化学与纳米医学重点实验室平台，并集聚多名中高水平中青年专家。研究院已经成为学科交叉特色鲜明的教学、科研、产业化人才“摇篮”。
研究院青年人才聚集，提倡自由学术探索，以学术兴趣和创新潜力为动力，积极鼓励跨学科合作与创新。经团队共同建设，研究院已形成“仁爱互助”、“快乐科研”、“争锋前沿”的文化氛围。目前，设立有核酸化学研究组、分子自组装与分子网络研究组、体外检测与诊断研究组、分子和纳米药物的临床转化等课题组。众多相关成果在Nature、Science和Nature系列等国际知名杂志上发表。近5年团队成员承担有国家重大科学研究计划、科技部重大专项、科技部重大仪器专项、国家杰青、优青基金等多项国家和省部级项目。2019年底，经上海市科委审批研究院正式启动“上海市核酸化学与纳米医学重点实验室”的建设工作。
研究院的实验平台布局合理，技术力量雄厚，仪器设备先进。配备有共聚焦扫描显微镜、轨道阱质谱仪、核磁共振仪、透射电镜、原子力显微镜、紫外光刻系统等多台大型精密仪器。
建院以来，研究院致力完善从基础研究到应用开发的完整创新成果产出。已与上海市三级甲等医疗单位开展临床合作研究，实现了基础研究和临床应用的紧密结合。
The Institute of Molecular Medicine (IMM), Shanghai Jiao Tong University School of Medicine, was established in October 2017 and led by Prof. Weihong Tan, who is academician of the Chinese Academy of Sciences. Based in Renji hospital, IMM focuses on cutting edge research of molecular medicine that aims to achieve scientific breakthrough in early diagnosis and drug innovation against major diseases, to promote the integration of basic research, intellectual property, and clinical translation, and ultimately to aid the realization of Health China. IMM, together with the Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine, now has many high-level scientists. To date, IMM has become the incubator for inter-disciplinary talents devoted to teaching, research, and technique translation.
IMM, which advocate free academic exploration, has gathered many young talents. We actively encourage interdisciplinary cooperation and innovation, driven by academic interest and innovation potential. Under the joint effort of the team, the institute has formed a cultural atmosphere of "Care and mutual assistance", "Happy scientific research" and "Striving for the frontier". At present, multiple research groups have been built including nucleic acid chemistry research group, molecular self-assembly and molecular network research group, in-vitro detection and diagnosis research group, molecular and nano-drug clinical transformation research group etc. Many research achievements have been published in top-notch international journals, such as Nature, Science, and Nature research journals. PIs from IMM have been supported by many national and provincial projects during the past 5 years, including Major Program of the National Natural Science Foundation of China, National Science and Technology Major Project of the Ministry of Science and Technology of China, National Science and Technology Major Project of the Ministry of Instrument of China, The National Science Fund for Distinguished Young Scholars, National Natural Science Foundation for Outstanding Young Scholars. At the end of 2019, the Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine based in IMM was approved by the Shanghai Science and Technology Committee.
The laboratory platform of the institute provides plentiful space and advanced instruments including confocal scanning microscopy, fully functional steady-state and transient fluorescence spectrometers, fluorescence real-time quantitative thermal circulator, high throughput DNA synthesizer, gel permeation chrommatography, flow cytometry, chemiluminescence imaging system, nucleic acid fragment analyzer, gas chromatography-mass spectrography, ultra-depth of field 3d microscopic system, UV lithography system, orbital trap mass spectrometer, nuclear magnetic resonance spectrometer, transmission electron microscope, atomic force microscope etc.
Since its inception, IMM has committed to promoting innovation from basic research to clinical application. Numerous clinical cooperative research projects with Shanghai First Class Grade 3A Hospitals have been initiated to facilitate the integration of basic research and clinical applications.
